Business Context and Reporting Period
Company: Indivior Pharmaceuticals, Inc. (INDV)
Filing Type: Form 8-K (Current Report)
Date of Report: February 26, 2026
Reporting Period: The filing announces financial results for the period ended December 31, 2025.
Key Financial Metrics
The provided Form 8-K text serves as a notification of results and does not contain specific financial data points. The filing references a press release (Exhibit 99.1) and presentation materials (Exhibits 99.2 and 99.3) for detailed figures.
- Revenue, Profit, Cash Flow, Margins: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
Material Changes
The filing text does not disclose specific material changes, year-over-year comparisons, or variance analysis. Investors must refer to the attached press release for details on operational changes versus the prior comparable period.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release and updated corporate presentation materials on February 26, 2026, which are included as exhibits to this report.
Guidance and Risks: No specific guidance, outlook, risk factors, or contingencies are detailed within the body of this 8-K filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net income, and cash flow figures for the year ended December 31, 2025.
- Examine Exhibit 99.2 and 99.3 for management's discussion of financial condition, strategic outlook, and any updated guidance.
- Verify the specific trading symbol INDV on The Nasdaq Stock Market LLC for current market reaction to the results.
- Confirm if the "Results of Operations" item (Item 2.02) in the full press release contains any non-GAAP reconciliations or unusual items not summarized here.